Twist Bioscience priced a $300 million public offering to fund R&D, manufacturing capacity expansion, and additional product offerings. The company set the share price at $96 and expects net proceeds of $300 million, with underwriters granted an option to purchase additional shares. The financing comes as Twist reported fiscal Q3 revenues of $118.4 million and raised full-year guidance, with management projecting triple-digit growth in AI revenues. Investors will likely focus on whether capacity additions translate into improved throughput for genomics services and whether AI-related revenues are scaling beyond pilots. For the sector, the move illustrates how public-market appetite is supporting wet-lab scaling commitments even as demand for genomic tooling and data-linked therapeutics continues to broaden.